(Q73351428)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12730893%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

0 references

1 reference

title

Is there a role for PPAR gamma in IBD? Yes, no, maybe (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12730893%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Is there a role for PPARγ in IBD? yes, no, maybe (English)

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(03)00345-7

30 December 2023

author name string

Gary D. Wu

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12730893

30 December 2023

language of work or name

English

0 references

publication date

1 May 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12730893%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

3 November 2019

https://api.elsevier.com/content/article/PII:S0016508503003457?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(03)00345-7

https://api.elsevier.com/content/article/PII:S0016508503003457?httpAccept=text/plain

30 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(03)00345-7

30 December 2023

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12730893%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

124

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12730893%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12730893%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

1538-1542

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12730893%20AND%20SRC:MED&resulttype=core&format=json

Peroxisome proliterator-activated receptors, orphans with ligands and functions

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

The organization, promoter analysis, and expression of the human PPARgamma gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Controversy: PPARgamma as a target for treatment of colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Emerging roles of PPARs in inflammation and immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

PPAR gamma is required for placental, cardiac, and adipose tissue development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

APC-dependent suppression of colon carcinogenesis by PPARgamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

What happened to drug trials in ulcerative colitis? Problems, PPARs, placebos, and (possible) progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

PPARgamma ligands: taking Ppart in chemoprevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900345-7

Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats

7 January 2021

series ordinal

14

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(03)00345-7

30 December 2023

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12730893%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference